赛托生物
(300583)
| 流通市值：32.24亿 | | | 总市值：32.86亿 |
| 流通股本：1.86亿 | | | 总股本：1.90亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 259,850,364.44 | 970,601,329.97 | 765,034,045.74 | 566,649,563.44 |
| 营业收入 | 259,850,364.44 | 970,601,329.97 | 765,034,045.74 | 566,649,563.44 |
| 二、营业总成本 | 285,808,740.98 | 1,025,141,490.76 | 744,755,228.96 | 553,897,255.29 |
| 营业成本 | 236,613,828.58 | 784,898,739.68 | 563,185,270.27 | 420,394,977.21 |
| 税金及附加 | 2,807,000.5 | 13,961,207.67 | 10,736,643.67 | 7,714,678.3 |
| 销售费用 | 2,346,104.69 | 15,182,898.36 | 12,355,834.63 | 9,182,050.56 |
| 管理费用 | 22,599,980.39 | 120,474,199.43 | 92,297,375.3 | 67,477,447.04 |
| 研发费用 | 10,449,182.96 | 58,379,409.91 | 41,391,541 | 31,496,849.65 |
| 财务费用 | 10,992,643.86 | 32,245,035.71 | 24,788,564.09 | 17,631,252.53 |
| 其中:利息费用 | 8,771,284.02 | 30,853,015.77 | 22,889,820.17 | 16,662,983.69 |
| 其中:利息收入 | 800,326.73 | 2,407,587.78 | 3,412,192.84 | 2,243,519.84 |
| 加:投资收益 | 2,770,396.94 | 12,349,077.69 | 10,869,510.28 | 9,671,230.51 |
| 资产处置收益 | - | 63,568.85 | -285,934.89 | -285,934.89 |
| 资产减值损失(新) | -5,679,426.72 | -75,091,679.09 | -21,710,361.39 | -6,926,755.13 |
| 信用减值损失(新) | -2,525,264.58 | 484,583.74 | 2,327,445.5 | -2,060,995.31 |
| 其他收益 | 2,094,882.38 | 14,671,923.73 | 9,702,493.42 | 6,224,900.44 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -29,297,788.52 | -102,062,685.87 | 21,181,969.7 | 19,374,753.77 |
| 加:营业外收入 | 4,210.01 | 472,365.65 | 126,774.48 | 112,633.98 |
| 减:营业外支出 | 460,579.35 | 1,158,551.79 | 574,653.15 | 550,641.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -29,754,157.86 | -102,748,872.01 | 20,734,091.03 | 18,936,746.72 |
| 减:所得税费用 | 2,198,782.66 | -1,420,606.43 | 7,533,431.14 | 5,965,795.37 |
| 六、净利润 | -31,952,940.52 | -101,328,265.58 | 13,200,659.89 | 12,970,951.35 |
| 持续经营净利润 | -31,952,940.52 | -101,328,265.58 | 13,200,659.89 | 12,970,951.35 |
| 归属于母公司股东的净利润 | -27,508,507.98 | -88,766,731.73 | 14,715,312.32 | 13,211,357.05 |
| 少数股东损益 | -4,444,432.54 | -12,561,533.85 | -1,514,652.43 | -240,405.7 |
| (一)基本每股收益 | -0.15 | -0.47 | 0.08 | 0.07 |
| (二)稀释每股收益 | -0.15 | -0.47 | 0.08 | 0.07 |
| 八、其他综合收益 | - | - | 1,097,419.76 | 1,097,419.76 |
| 归属于母公司股东的其他综合收益 | - | - | 1,097,419.76 | 1,097,419.76 |
| 九、综合收益总额 | -31,952,940.52 | -101,328,265.58 | 14,298,079.65 | 14,068,371.11 |
| 归属于母公司股东的综合收益总额 | -27,508,507.98 | -88,766,731.73 | 15,812,732.08 | 14,308,776.81 |
| 归属于少数股东的综合收益总额 | -4,444,432.54 | -12,561,533.85 | -1,514,652.43 | -240,405.7 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |